GlobeNewswire

VeriTransfer(TM) Unveils the First Known Proof-of-Concept for a Blockchain Enabled Firearms Licence Verification and Ownership Transfer

Dela

Blockchain Enabled Firearms Solution Ensures Instant Verification of Ownership and Safe Transfer While Maintaining Data Privacy

  

 

TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- VeriTransfer(TM) today announced the completion of its Proof-of-Concept ("POC") of the first publicly announced Blockchain enabled solution that decentralizes the process of storing the ownership rights and transfer of firearms.

VeriTransfer(TM) is also pleased to announce that it will donate a percentage of all future revenues or the proceeds from any future sale of the company towards foundations whose mission is to end gun violence and build safer communities.

The Gun Epidemic & The Economic Impact

The United States hosts 4.4% of the world's population, but almost 50% of the 644 million civilian-owned guns globally are located in the U.S. Disturbingly, more American citizens have died as a result of gunshots in the U.S. since 1968 than on the battlefield of all the wars in American history from 1175 to 2015. In addition, the estimated annual cost of fatal and non-fatal gun violence to the U.S. was $229 billion, representing 1.4% of total GDP1.

There have been 154 mass shootings in the United States since January 1st, 2018. This includes 23 school shootings that have occurred as of June 30th, 2018 in the U.S. where someone was either hurt or killed. That averages out to more than one school shooting a week2.                                 

The Potential Bipartisan Solution

VeriTransfer's mission is to help increase public safety, mitigate firearm-related deaths, all while empowering firearm owners to safely manage the ownership of their firearms and maintain complete data privacy. The decentralized and private structure of the VeriTransfer system gives full ownership of firearm data to the licence holder, while empowering law-abiding citizens to reduce the flow of firearms into criminal or suicidal hands.

Mathieu Glaude, CEO of Northern Block, the Toronto-based blockchain product development company is excited about VeriTransfer's potential societal impact. "We see the management of firearms as a perfect use case for blockchain technologies. Empowering individuals and retailers to privately manage their firearms in a decentralized manner is powerful and it presents an optimal solution to the unresolved gun control problem." said Glaude.

"We are incredibly excited to be involved in a real-world use case of blockchain technologies that has the potential to save lives," said Kesem Frank, COO of AION. "This is all achieved while maintaining data privacy and has the potential to eliminate data silos within government agencies."

VeriTransfer is a distributed system that decentralizes the storage of the ownership of firearms. The application makes it easy for any licenced firearm owner/retailer to manage their firearm inventory. Additionally, firearm holders can use VeriTransfer to digitally store a Government-issued licence, if applicable. VeriTransfer makes it simple for users to transfer firearm ownership at point-of-sale (B2B or B2C) or between licence holders (C2C) by scanning a QR code of the purchaser's licence using their mobile device. Additionally, firearm retailers can use VeriTransfer to perform licence eligibility checks prior to transferring firearm ownership to another person (e.g., selling a restricted firearm).

VeriTransfer is not a gun registry, it's a decentralized application that gives full ownership of firearm data to the licence owner. Firearm owners can be confident that their firearm data remains private and in their control at all times. Details about someone's identity, firearm licence (if applicable), and firearm ownership remain fully confidential and can only be accessed by external parties if consent is provided.

With blockchain technologies, the VeriTransfer decentralized application (dApp) uses permissioned smart contracts for users to access data from the blockchain. Firearms are turned into unique digital tokens, similar to the ERC-721 non-fungible token standard developed for Ethereum. These unique tokens are tied to engraved serial numbers or RFID-chipped firearms. Firearm ownership can be transferred between licence holders by sending these tokens electronically between the blockchain addresses of the licence holders. There's no need for users to acquire tokens, since they are automatically created through the system every time a firearm is added to the network.

Technology Overview

AION Blockchain

AION is an all-in-one blockchain network that enables hybrid architectures, scalability and interoperability for solutions built on top of it. AION allows building interoperable permissioned blockchains that has the ability to scale to an enterprise level.

Key Smart Contracts

Many functions of VeriTransfer (TM) rely on smart contracts within AION. A smart contract is a collection of code and data that resides on a specific blockchain address. They can facilitate, verify and enforce access to blockchain data between different users. Smart contracts can be described as a specific data slot on a blockchain that can be queried and changed by calling its functions. 

In VeriTransfer (TM), a firearm licence holder's data is managed through the following smart contracts: 

1. Licensing Smart Contract. Anytime a firearm licence is issued to an individual, a transaction is sent to VeriTransfer's permissioned blockchain. This smart contract records the fact that a person has a licence and stores the hashed validation of this fact to the permissioned blockchain. This allows for immutable track records of firearm holders to be kept on the blockchain.

2. Firearms Smart Contract. This maintains the record of gun ownership represented by a digital token within the contract and associates it with a specific individual. Retailers and firearms holders can pass the ownership from one to another, and the smart contract will facilitate the transfer of the digital token between users that are registered on a blockchain and have a blockchain address.

These two smart contracts interact with one another. Every new firearm registered in the system creates a new unique token that can be associated with a dealer's / individual's blockchain address.

Conclusion

The completion of the VeriTransfer (TM) Proof-of Concept is significant, as this process and key technology can be replicated in a bespoke manner for the US market, while dually maintaining data privacy without violating the Second Amendment of the United States Constitution. VeriTransfer is currently in discussions with various parties in order to commence a Pilot Project in Canada and/or the United States with selected firearms dealers and government agencies.  You can find a link to our Whitepaper and video demo of the application here:  Veritransfer.io

About VeriTransfer (TM)

VeriTransfer (TM), is the first known Blockchain enabled distributed system that decentralizes the process of the storage of the ownership rights, and transfer of firearms.

Key Contacts

Mark Lawson
VeriTransfer(TM) 
T: +1 647 256 1986 
mark@veritransfer.io

Mathieu Glaude
CEO, Northern Block Inc.
T: +1 647 991 8863
mathieu@northernblock.ca

Kesem Frank
COO, AION
T: +1 647 970 3736
kesem@mavennet.com

References:

  1. Michelle Singletary, The Washington Post, February 22, 2018; Mother Jones Report.
  2. Gun Violence Archive, 2018.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/830e7a9e-b315-46f6-8a35-a0b46d84dc81




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VeriTransfer via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum